Streetbeat News

Regulatory

GRPN

Groupon has notified Nasdaq that it is not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) but intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 9:12 pm

MF

Missfresh has received a minimum bid price notice from Nasdaq and has been given a compliance period of 180 days, until December 11, 2023, to regain compliance under the Nasdaq Listing Rules.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 9:04 pm

ALGS

Aligos Therapeutics presented data from its liver disease programs at the European Association for the Study of the Liver Congress 2023, showcasing the progress of its research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:33 pm

TRKA

Troika Media Group Inc has regained compliance with Nasdaq's minimum bid price rule on June 20, according to Nasdaq staff notification.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 8:28 pm

BLK

BTCUSD

WisdomTree has submitted a request for approval of its Bitcoin Trust ETF, targeting a listing on the Cboe BZX Exchange. This follows a similar initiative by BlackRock, reflecting the growing interest in Bitcoin within traditional finance.

Portfolio Pulse from Murtuza Merchant

June 21, 2023 | 8:21 pm

F

GM

TSLA

17 Democrats in Congress have urged the Federal Trade Commission (FTC) to finalize new rules to protect car buyers, potentially affecting automakers like Ford, General Motors, and Tesla.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 8:20 pm

MFIN

Medallion Financial Corp has filed for a mixed shelf offering of up to $100 million, according to a recent SEC filing.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 8:15 pm

NXTC

NextCure presented non-clinical data on the mechanism of NC525 at the Federation of Clinical Immunology Societies annual meeting. NC525 is a humanized monoclonal antibody that targets LAIR-1 and is being developed for the treatment of advanced myeloid leukemias. The company plans to provide an update on the trial in the fourth quarter of this year.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 8:07 pm

MRNS

Marinus Pharmaceuticals (NASDAQ: MRNS) has been granted a new method of use patent by the USPTO for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. This is the company's second method of use patent for IV ganaxolone in SE, further strengthening its intellectual property position.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 8:04 pm

ATVI

Activision Blizzard shareholders approved all board nominees and voted in favor of company recommendations on all proposals. One proposal was withdrawn after the company released its inaugural Transparency Report, highlighting efforts to promote a diverse and inclusive workplace.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:02 pm